Charles Darwin University

CDU eSpace
Institutional Repository

CDU Staff and Student only

Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: Results of a phase 1 randomized controlled trial

Thera, Mahamadou A., Doumbo, Ogobara K., Coulibaly, Drissa, Diallo, Dapa A., Kone, Abdoulaye K., Guindo, Ando B., Traore, Karim, Dicko, Alassane, Sagara, Issaka, Sissoko, Mahamadou S., Baby, Mounirou, Sissoko, Mady, Diarra, Issa, Niangaly, Amadou, Dolo, Amagana, Daou, Modibo, Diawara, Sory I., Stewart, V. Ann, Leach, Amanda J., Plowe, Christopher V. and et al. (2008). Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: Results of a phase 1 randomized controlled trial. PLoS One,3(1):e1465-1-e1465-11.

Document type: Journal Article
Attached Files (Some files may be inaccessible until you login with your CDU eSpace credentials)
Name Description MIMEType Size Downloads
Download this reading Leach_44356.pdf Published version application/pdf 213.96KB 201
Reading the attached file works best in Firefox, Chrome and IE 9 or later.

IRMA ID 75039815xPUB514
Title Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: Results of a phase 1 randomized controlled trial
Author Thera, Mahamadou A.
Doumbo, Ogobara K.
Coulibaly, Drissa
Diallo, Dapa A.
Kone, Abdoulaye K.
Guindo, Ando B.
Traore, Karim
Dicko, Alassane
Sagara, Issaka
Sissoko, Mahamadou S.
Baby, Mounirou
Sissoko, Mady
Diarra, Issa
Niangaly, Amadou
Dolo, Amagana
Daou, Modibo
Diawara, Sory I.
Stewart, V. Ann
Leach, Amanda J.
Plowe, Christopher V.
et al.
Journal Name PLoS One
Publication Date 2008
Volume Number 3
Issue Number 1
ISSN 1932-6203   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-44849126049
Start Page e1465-1
End Page e1465-11
Total Pages 11
Place of Publication United States
Publisher Public Library of Science
HERDC Category C1 - Journal Article (DIISR)
Abstract Background:
The objective was to evaluate the safety, reactogenicity and immunogenicity of the AMA-1-based blood-stage malaria vaccine FMP2.1/AS02A in adults exposed to seasonal malaria.

Methodology/Principal Findings:
A phase 1 double blind randomized controlled dose escalation trial was conducted in Bandiagara, Mali, West Africa, a rural town with intense seasonal transmission of Plasmodium falciparum malaria. The malaria vaccine FMP2.1/AS02A is a recombinant protein (FMP2.1) based on apical membrane antigen-1 (AMA-1) from the 3D7 clone of P. falciparum, adjuvanted with AS02A. The comparator vaccine was a cell-culture rabies virus vaccine (RabAvert). Sixty healthy, malaria-experienced adults aged 18–55 y were recruited into 2 cohorts and randomized to receive either a half dose or full dose of the malaria vaccine (FMP2.1 25 µg/AS02A 0.25 mL or FMP2.1 50 µg/AS02A 0.5 mL) or rabies vaccine given in 3 doses at 0, 1 and 2 mo, and were followed for 1 y. Solicited symptoms were assessed for 7 d and unsolicited symptoms for 30 d after each vaccination. Serious adverse events were assessed throughout the study. Titers of anti-AMA-1 antibodies were measured by ELISA and P. falciparum growth inhibition assays were performed on sera collected at pre- and post-vaccination time points. Transient local pain and swelling were common and more frequent in both malaria vaccine dosage groups than in the comparator group. Anti-AMA-1 antibodies increased significantly in both malaria vaccine groups, peaking at nearly 5-fold and more than 6-fold higher than baseline in the half-dose and full-dose groups, respectively.

The FMP2.1/AS02A vaccine had a good safety profile, was well-tolerated, and was highly immunogenic in malaria-exposed adults. This malaria vaccine is being evaluated in Phase 1 and 2 trials in children at this site.

DOI   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)

© copyright

Every reasonable effort has been made to ensure that permission has been obtained for items included in CDU eSpace. If you believe that your rights have been infringed by this repository, please contact

Version Filter Type
Access Statistics: 186 Abstract Views, 201 File Downloads  -  Detailed Statistics
Created: Tue, 24 Feb 2015, 12:38:12 CST